Comparison Study of Two Treatment Modalities i.e. Calcipotriol Ointment and Calcipotriol Ointment Along With Ultraviolet Phototherapy in Special Kind of Hairloss Disorder Called as Alopecia Areata

Phase 3

Completed

Conditions: Health Condition 1: null- PATIENTS OF ALOPECIA AREATA WITH GOOD GENERAL CONDITION AND FREE FROM ANY MAJOR SYSTEMIC ILLNESS.

Registration Number: CTRI/2015/11/006363

Lead Sponsor: DEPARTMENT OF SKIN AND VD

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 60

Inclusion Criteria

Patients of any age > 5 yrs, showing features of alopecia areata

- Patients with a diagnosis of patch type alopecia areata or alopecia totalis

- No evidence of regrowth present at baseline.

- Patient should be free from other modalities of treatment atleast for two weeks.

Exclusion Criteria

- Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis.

- Patients in whom the diagnosis of alopecia areata is in question.

- Patients with active medical conditions and other comorbid conditions like infection, eczematization that in the opinion of the investigator would alter the outcome of study evaluation.

- Patients with history or evidence of hematopoietic abnormality

- Patients with history or evidence of renal or hepatic impairment.

- Patients with history of immunosuppression or history of recurrent serious infections.

- History of photodermatitis or photosensitivity

- Patients taking oral corticosteroids or applying topical corticosteroids or treatment from outside.

- Patients with allergy to any component of calcipotriol preparation

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HAIR GROWTH ASSESSMENT WILL BE DONE CLINICALLY BY PHOTOGRAPH WITH SEVERITY OF ALOPECIA AREATA TOOL SCORING AND BY TRICOSCAN INITIALLY, AFTER 4 WEEKS AND FINALLY AFTER 12 WEEKS.Timepoint: 4 weeks <br/ ><br>12 weeks or complete resolution of alopecic lesion, whichever come first

Secondary Outcome Measures